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Chinese hamster ovary (CHO) cells are the leading mammalian cell expression platform for 
biotherapeutic recombinant molecules yet some proteins remain difficult to express (DTE) in this, 
and other, systems. In recombinant cell lines expressing DTE proteins, cellular processes to restore 
proteostasis can be triggered when the folding and modification capabilities are exceeded, including 
the unfolded protein response and ER-associated degradation (ERAD) and proteasomal 
degradation. We therefore investigated whether the proteasome activity of CHO cells was linked to 
their ability to produce recombinant proteins. We found cell lines with diverse monoclonal antibody 
(mAb) productivity show different susceptibilities to inhibitors of proteasome activity. Subsequently, 
we applied selective pressure using proteasome inhibitors on mAb producing cells to determine the 
impact on cell growth and recombinant protein production, and to apply proteasome selective 
pressure above that of a metabolic selection marker during recombinant cell pool construction. The 
presence of proteasome inhibitors during cell pool construction expressing two different model 
molecules, including a DTE Fc-fusion protein, resulted in the generation of cell pools with enhanced 
productivity. The increased productivities, and ability to select for higher producing cells, has 
potential to improve clonal selection during upstream processes of DTE proteins.  
 
Keywords: Proteasome inhibitors; Chinese hamster ovary cells; ERAD; recombinant protein 
production, difficult to express proteins. 
 
Abbreviations: CHO, Chinese hamster ovary cells; DMSO, dimethyl sulfoxide; DTE, difficult to 
express; ERAD, endoplasmic reticulum associated degradation; GS, glutamine synthetase; mAb, 





1. Introduction  
The Chinese hamster ovary (CHO) cell host expression system is widely employed for the 
commercial production of an ever-increasing number of biotherapeutic proteins. This is largely due 
to its ability to undertake human-like post-translational modifications, such as glycosylation, and to 
correctly fold, assemble and secrete multi-domain/polypeptide chain containing molecules with high 
yield and quality (Feary, 2017; Kunert, 2016; Mead, 2015; Povey, 2014; Walsh, 2018). One of the 
largest class of molecules expressed in this system is that of monoclonal antibodies (mAbs). CHO 
cell expression systems and associated bioprocesses have been developed through a range of 
approaches over the last few decades such that yields in excess of 5 g/L of mAb are now routinely 
achieved (Marichal-Gallardo, 2012). However, some mAbs are still difficult to express (DTE) in CHO 
cells (Laux, 2013; Mathias, 2020; Pybus, 2014) whilst many novel biotherapeutic molecule formats 
in development are DTE in CHO cells, or any other, expression system. A number of approaches 
have been taken to try and address this so that such DTE proteins can be produced at higher yields 
and quality.  Approaches include: engineering of the target protein (Grote, 2012), screening of 
different bioprocesses, media and additives (Pybus, 2014) engineering of lipid metabolism (Budge, 
2020), and  manipulation of the unfolded protein response (UPR) and protein degradation (Johari, 
2015; Le Fourn, 2014; Pybus, 2014). Indeed, Mathias et al have reported that DTE monoclonal 
antibodies have hampered secretion, and thus low secretory product yields, due to misfolding, and 
that as a result these molecules are degraded intracellularly by the proteasome (Mathias, 2020). 
This degradation does not allow the cell to recover synthesised but incorrectly folded polypeptides, 
reducing potential yields. There is thus an interest in furthering our understanding of the cellular 
properties that underpin productivity of DTE mAbs and other molecules, and whether a knowledge 
of these can be used to help evolve or select high producing host and recombinant CHO cell lines.  
As highlighted by Mathias et al (2020), in a recombinant cell line expressing a DTE protein, particular 
cellular processes can be triggered within the cell when the folding and modification capabilities of 
the enzymes and chaperones within the ER are exceeded, to restore proteostasis. Two of the 
processes initiated to deal with misfolded or unassembled polypeptides during protein synthesis are 
the induction of the unfolded protein response (UPR) during ER stress and the activation of 
ER-associated degradation (ERAD) and proteasomal degradation. Key responses activated by 
these processes include up-regulation of ER chaperones, a reduction in global protein synthesis and 
thus the amount of new polypeptides entering the ER and ultimately, if the stress persists, apoptosis 
(Chakrabarti, 2011; Schroder, 2005). Indeed, it is proposed that up to 30% of newly translated 
polypeptides are targeted for degradation, possibly as a result of misfolding (Du, 2013; Schubert, 
2000; Yewdell, 2006). It is thought that this cellular activity not only helps maintain protein quality, 
but that proteasomal degradation of polypeptides allows for amino acid recycling so that these are 
available to support further protein synthesis (Bröer, 2017; Suraweera, 2012). 
The two cellular processes of the UPR and ERAD are coordinated, with the induction of a UPR 
response leading to an increased ERAD capacity. ERAD requires that polypeptides/proteins in the 
ER destined for destruction are transported back out of the ER to the cytosol where they are 
degraded by the proteasome (Olzmann, 2013). If homeostasis cannot be restored then the 
processes activated by the UPR can ultimately lead to apoptosis. The UPR provides the cell with the 
capability to adjust ER capacity during periods of high demand and an element of UPR induction is 
proposed to be beneficial to recombinant protein production (Prashad, 2015). However, excessive 
and long-term activation can be detrimental to the cell, and therefore the activation and tuning of the 
UPR and ERAD are thought to be related to the productivity and quality of the recombinant proteins 
generated. When a cell has the burden of recombinant polypeptides entering the ER, the ER can be 
placed under additional stress resulting in the UPR being induced (Hussain, 2014). It follows that 
concomitant with this, increased ERAD activity would be observed to maintain protein quality, reduce 
ER stress and meet the demands of high levels of recombinant protein production. Indeed, during 
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the differentiation of B cells into antibody producing plasma cells there is a programmed and 
coordinated expansion of the ER, ER chaperones, energy metabolism and ERAD to meet the 
demands of antibody synthesis (Aragon, 2012; Ma, 2010; Shaffer, 2004). Further, as described 
above, Mathias et al (2020) reported that a DTE mAb was misfolded, and degraded intracellularly 
by the proteasome.  
We therefore explored whether the capability of CHO cells to undertake protein turnover via the 
proteasome is linked to their ability to produce a model mAb and DTE Fc-fusion protein. We 
hypothesized that those cells with a greater capacity for protein turnover would have higher 
recombinant protein productivity and quality attributes and that cells could be selected for, or 
evolved, that had improved recombinant protein production attributes using specific inhibitors of 
proteasomal activity. To investigate this, we established whether cells of different mAb productivity 
showed different susceptibilities to inhibitors of proteasomal activity. Subsequently, we applied 
selective pressure using proteasome inhibitors on mAb producing cells to determine any impact on 
cell growth and recombinant protein production. Inhibitors were then also used to apply proteasome 
selective pressure above that of a metabolic selection marker during a recombinant cell pool 
construction process and the resulting cell pools that emerged analyzed for growth and recombinant 
protein productivity. Finally, we undertook analysis of proteasome inhibitor evolved cells using qPCR 
arrays to identify changes in gene expression between control and inhibitor treated cells.  
 
2. Methods and Materials 
2.1 Cell lines and cell culture The Lonza CHOK1SV GS-KO® host cell line was cultured in CD 
(chemically defined)-CHO media (Invitrogen) supplemented with 6 mM glutamine; stably producing 
recombinant cell pools (used to generated the proteasome inhibition susceptibility correlation data) 
were cultured in CD-CHO media supplemented with 25 M L-methionine sulfoximine (MSX), under 
batch culture conditions at 140 rpm, 36.5oC with 5% (v/v) CO2. Cells were passaged approximately 
every 3 to 4 days by performing a cell count using a ViCell XR (Beckman Coulter) instrument to 
determine viable cell concentrations, and resuspending the required volume to achieve seeding at 
0.2 x 106 viable cells/ml in fresh media.  
2.2 Inhibitor kill curves in 96 DWP format 96 deep well plates (Nunc) were seeded at 4 x 106 
viable cells/ml/well for analysis of proteasome inhibitor effects. Triplicate wells were prepared for 
each inhibitor, for each panel of cell lines. 1 l of each inhibitor stock was added to each well to give 
a final concentration of 0.05 M Epoxomicin or 0.5 M MG-132. Plates were then incubated at 
36.5oC, 5% CO2. Cell concentration and culture viability was measured using a ViCell instrument. 
The remaining culture was centrifuged at 1000 rpm for 5 minutes and the supernatant and pellet 
stored at -20oC prior to further analysis. 
2.3 Polyclonal stable pool generation Linearization of the appropriate Lonza proprietary plasmid 
DNA was first performed with the PvuI restriction enzyme (New England Biolabs). Successful digests 
(assessed on a 1% agarose gel) were then concentrated and cleaned using a commercially available 
PCR clean up kit (Qiagen) and ethanol precipitation. The final DNA pellet was resolubilized in 0.2 
µm filter sterilized 1 x TE buffer (Qiagen) in an appropriate volume required for the subsequent 
transfections and left at room temperature for approximately 1 hour, before determining the final 
DNA concentration of the linearized plasmid using a Nanodrop instrument. Subsequent transfection 
of the linearized plasmid DNA was then performed by electroporation using a GenePulser Xcell 
electroporator (Bio-Rad) into the Lonza CHOK1SV GS-KO® suspension cell line. Cells were taken 
from culture in mid exponential phase to achieve a concentration of 1 x 107 viable cells and combined 
with an appropriate quantity of linearized plasmid DNA in a BioRad electroporation cuvette. The 
DNA/cell mix was electroporated at 300 V and 900 uF in a cuvette with a 0.4 cm gap. For the cell 
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pool construction experiment, multiple electroporations were pooled together to give the required 
final volume. This electroporation pool was thoroughly mixed and then distributed in 10 ml volumes 
between T75 tissue culture flasks and incubated statically at 36.5oC with 5% CO2. 24 hours post-
transfection, the glutamine synthetase inhibitor MSX was added at final concentrations of either 25, 
37.5 or 50 M. The addition of the proteasome inhibitors was then performed at the appropriate 
time-point following MSX selection as determined by the design of experiments layout detailed in 
Supplementary Figure 1. 0.2 m filter sterilized DMSO was added as a control. Cultures were kept 
statically at 36.5oC and 5% CO2 until a viable cell concentration of at least 0.2 x 106 cells/ml was 
achieved, following which the cultures were transferred into 20 ml shake flask cultures at 36.5oC and 
5% CO2 with shaking at 140 rpm. Routine sub-culture was then performed every 3 to 4 days in 
CD-CHO media with the addition of the appropriate MSX and proteasome inhibitor concentrations 
to the fresh cultures.  
2.4 Batch culture assessment of cell pools generated from the proteasome inhibitor 
containing cell pool construction process For this purpose, cells were seeded at a concentration 
of 0.2 x 106 viable cells/ml in triplicate flasks, without the addition of the proteasome inhibitors, and 
incubated at 37oC with shaking at 140 rpm in a Kuhner incubator and sampled every 48 to 72 hours 
for the determination of cell concentration and culture viability on a ViCell instrument. 
2.5 Protein A high performance liquid chromatography to determine antibody concentration 
HPLC was performed with a Protein A column using Chemstation software and Agilent 1260 
instrument following Lonza standard operating procedures.  
2.6 Octet analysis to determine antibody concentration Recombinant molecule concentrations 
in cell culture supernatant samples were determined using the ForteBIO Octet® QKe system and Dip 
and Read™ Protein A Biosensors (18-5013). Appropriate standard curves were prepared by dilution 
of a known concentration of the recombinant molecule being assessed. Specific productivity (Qp) 
values were determined from three time points of culture where product concentration and viable 
cell concentration using the ViCell instrument (Beckman Coulter) had been assessed. Qp was 
determined from the gradient of the line when average integral of viable cells (IVC) was plotted 
versus the average product concentration. 
2.7 Glycan profiling Was undertaken internally at Lonza Biologics Analytical Research and 
Technology group. In brief, N-linked glycans were removed with peptide N-glycosidase F, labelled 
with 2-aminobenzamide and analysed by hydrophilic interaction chromatography with fluorescent 
detection. 
2.8 RT2 Profiler PCR array for CHO cell unfolded protein response Cell pools were revived and 
passaged four times in CD-CHO media supplemented with 37.5 M MSX and incubated at 36.5oC 
with 5% CO2 at 140 rpm. Cell pellets of 2 x 106 viable cells were taken on days 3, 5 and 6 of culture 
and resuspended in 350 l RLT buffer (Qiagen), before storage at -80oC. The recombinant mAb 
protein expression profile of the cell pools was confirmed by western blot to be similar to the profile 
achieved immediately after the original cell pool construction. RNA extraction was performed on cell 
pellets using the Qiagen RNeasy mini kit as per the manufacturer’s instructions, with the use of 
QiaShredder columns to lyse the cells. An on column DNase I treatment (Qiagen) was also 
performed on all samples and extracted RNA stored at 80oC prior to array analysis. RNA 
concentration was determined using a Nanodrop 1000 spectrophotometer. A denaturing 
formaldehyde gel was run in MOPS buffer to assess RNA samples for additional degradation 
products or genomic DNA. The RT2 Profiler PCR Array manual was followed for analysis with the 
initial genomic DNA elimination performed with 1 g RNA followed by reverse transcription and 
RT-PCR with the RT2 SYBR Green mastermix using a Eppendorf® Mastercycler ep realplex model 
4S instrument in a 96 well plate format. Data analysis was performed using the ΔΔCT method as 
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available on the PCR Array Data Analysis Web portal at 
www.SABiosciences.com/pcrarraydataanalysis.php. 
2.9 Statistical analysis Correlation analysis was undertaken using linear regression and Pearson’s 
correlation analysis. Analysis was performed in SigmaPlot 12.5 using linear regression analysis and 




3.1 The susceptibility of a panel of recombinant mAb producing CHO cell lines to proteasome 
inhibition correlates to mAb yield and mAb cell specific production  
Initially we evaluated the impact on cell growth and culture viability of a panel of mAb producing cell 
lines of different productivities in the presence of different concentrations of proteasome inhibitors. 
These industrially relevant cell lines have been previously described (Porter, 2010a; Porter, 2010b). 
The proteasome inhibitors epoxomicin, a naturally occurring irreversible inhibitor, and MG-132, a 
reversible inhibitor, were added to the culture media of cells. Both compounds are well studied, 
selective and potent inhibitors of the proteasome (Hofmeister-Brix, 2013; Meng, 1999).  
We first performed experiments using one model recombinant CHO mAb producing cell line to 
determine appropriate concentrations of each inhibitor for the assessment of the full panel. The 
concentrations analyzed were based on those concentrations previously reported in the literature; 
0.04 to 0.08 M epoxomicin has been shown to inhibit chymotrypsin activity of the proteasome 
(Meng, 1999); 1.5 M MG-132 has been shown to induce apoptosis (Meriin, 1998). Both inhibitors 
were formulated in DMSO and DMSO alone was used as a negative control. We used these as 
starting concentrations to identify concentrations of inhibitors that gave some selection pressure (e.g. 
not all cells survived) on CHO cell lines but did not result in complete cell death, setting a criteria of 
addition of inhibitor concentrations giving a culture viability of between 30-60% 48 h after addition. 
Based on the observed culture viability and viable cell concentration up to 168 hours after exposure 
to the two inhibitors during batch culture, the concentrations deemed most appropriate for further 
studies were those around 0.5 M for MG-132 and above 0.05 M for epoxomicin. At these 
concentrations, an impact on viable cell concentrations and culture viability was observed with an 
approximate 30 to 60% reduction compared to control samples (Figure 1). At higher concentrations 
there was more cell death or the cultures were killed completely whilst at lower concentrations there 
was little or no impact on viable cell concentrations or culture viability (Figure 1). We note that the 
control DMSO experiments for MG-132 and epoxomicin gave different profiles that related to the 
final concentration of DMSO present in the culture (1.25 v 2.8% v/v respectively, Figure 1). The 
concentrations selected for further study were thus a compromise between the impact on the cell 
numbers that survived the presence of the inhibitor, and therefore potentially on selection of cells, 
and complete cell death. 
The impact of the two inhibitors at the established concentrations were then investigated on a panel 
of CHO mAb producing cell lines, all derived from the Lonza CHOK1SV® host cell line and that were 
expressing the model IgG4 molecule at different yields. The viable cell concentration and culture 
viability were assessed after addition of the inhibitors (and control DMSO alone) in a 96 deep well 
plate format, with daily cell concentration being estimated using a ViCell instrument. The viable cell 
concentration and culture viability of the cell lines on different days post-inhibitor addition were then 
related to the productivity of the cell lines to establish if there was any correlation between cell line 
mAb productivity and susceptibility to the proteasome inhibitor concentrations investigated. Historical 
productivity data from shake flask fed batch and bioreactors were used to perform linear regression 
and Pearson’s correlation analysis between viable cell concentration and culture viability in the 96 
DWP format with product titre and cell specific productivity (Figure 2). The 48 hours post-addition 
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time-point was used to perform correlation analyses as at this time point the majority of inhibitor and 
inhibitor concentration combination cultures had culture viabilities above 30%. Statistically significant 
correlations (p <0.05) were observed between antibody concentration at harvest and susceptibility 
(viable cell concentration and culture viability) of the cell line to the presence of the proteasome 
inhibitors (Figures 2B & 2D). This was also the case for cell specific productivity (Figures 2A, 2C, 
2E-F), suggesting a link between susceptibility of a cell line to proteasome inhibitors, culture viability 
and the ability to produce mAb.  
3.2 Proteasome selection pressure during cell pool construction results in the isolation of 
cell pools with enhanced recombinant mAb expression compared to those generated in the 
absence of proteasome inhibitors  
Due to the correlation observed between cell line productivity and susceptibility of cell lines to 
proteasome inhibitors (Figure 2), we next investigated whether proteasome inhibitor presence could 
be used to select for or isolate higher mAb producing recombinant cell pools during a cell pool 
construction process. A cell pool construction process was therefore designed to generate Lonza 
CHOK1SV GS-KO® recombinant mAb producing cell pools using the model cB72.3 antibody. This 
was achieved by including the addition of the proteasome inhibitors as an additional selection 
pressure to Lonza’s proprietary glutamine synthetase (GS®) metabolic selection system using a 
proprietary vector with the GS® gene in addition to the heavy and light chain mAb gene and addition 
of methionine sulphoximine (MSX) during recovery of transfected cells (Fan, 2012). The cell pool 
construction process design is described in Supplementary Figure 1 and was developed using a 
design of experiments (DoE) approach. Cells were transfected and then MSX added after 24 hours 
in glutamine free medium to aid metabolic selection for those cells that had GS® expression whilst 
the proteasome inhibitors were added 24, 96 or 168 hours post addition of MSX to allow selection 
based on plasmid uptake to occur prior to inhibition of the proteasome. The staggered addition of 
MSX and proteasome inhibitors was also undertaken to limit the impact of applying two inhibitors 
onto cells at the same time. Addition of DMSO alone was again used as a negative control as both 
proteasome inhibitors tested were prepared in this solvent (one or both being insoluble in other 
alternatives such as ethanol). 
When undertaking the cell pool construction process, the concentrations of MG-132 used were lower 
than those used previously to generate the data presented in Figure 2. The concentrations previously 
investigated with the panel of recombinant mAb cell lines resulted in poor viable cell concentrations 
following electroporation and during the cell pool construction process, likely due to the impact of 
electroporation and MSX challenge on top of MG-132. As a result, the concentration of MG-132 used 
during cell pool construction was decreased and either 0.0625 or 0.125 M were used in experiments 
whilst 0.025 or 0.05 M epoxomicin were used. Combinations of the two proteasome inhibitors were 
also investigated (Supplementary Figure 1), however this combination approach or the use of higher 
concentrations of inhibitor did not appear to be tolerated by the cells following the transfection 
process.  
Eight out of the thirty cell pool construction processes evaluated survived the cell pool construction 
process (Figure 3). These were the four controls treated with different MSX concentrations and with 
DMSO alone (i.e. no proteasome inhibitor was added) and four where the process contained the 
lower concentration of either MG-132 (0.0625 M) or epoxomicin (0.025 M) after addition of MSX. 
These cell populations were cultured and expanded in the presence of both MSX and the appropriate 
concentration of the proteasome inhibitors before being assessed in a suspension batch culture for 
growth and antibody productivity characteristics. In general, the growth characteristics were similar 
between all the cell populations (Figure 3). One of the cell pool constructions undertaken in the 
presence of 0.025 M epoxomicin and 37.5 M MSX grew slower than the other cultures and did 
not achieve as high a maximum viable cell concentration, obtaining a maximum viable cell 
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concentration of 5.33 x 106 cells/ml in comparison to 8 to 10 x 106 cells/ml for the other cell pool 
construction populations (Figure 3A). One of the two cell pool populations generated in the presence 
of MSX and DMSO alone declined in culture viability at an earlier time point compared to the other 
populations, to a viability of 5.8% at 192 hours of culture (Figure 3B).  
Analysis of the antibody concentration in the supernatant demonstrated a large difference in the 
concentration between pools generated using the different cell pool construction processes. The 
antibody concentration was determined from supernatant taken at 192 hours of batch culture using 
Protein A HPLC (Figure 3C). All cell pools isolated in the presence of the proteasome inhibitors 
showed an increase in antibody concentration over that observed from the MSX and DMSO 
generated pools alone. Indeed, those pools generated with 0.0625 M MG-132 and 37.5 M MSX 
showed an approximate 3-fold increase in the amount of antibody present in the cell culture 
supernatant, whereas those generated with 0.025 M epoxomicin and 37.5 M MSX also displayed 
at least a 3-fold increase, and in one case an approximate 6-fold increase in antibody concentration 
over the different control pools generated with MSX and DMSO alone (Figure 3C). These data 
suggest that the use of the proteasome inhibitors alongside MSX selection results in the generation 
of cell pools that have higher recombinant monoclonal antibody productivity than those generated 
using MSX selection alone, being at least 3-fold, although the exact magnitude of the increase 
showed some variability and in some cases was larger. 
3.3 The presence of proteasome inhibitors during cell pool development does not negatively 
impact critical quality product attributes such as N-glycosylation  
We next investigated whether using inhibitors of proteasome degradation of mis-assembled proteins 
had an impact on the quality of the final recombinant product produced, specifically the 
N-glycosylation profile. To determine whether the presence of the inhibitors had any impact on the 
N-glycan profile of the model mAb, UPLC analysis was performed to assess the major N-glycoforms 
present in control and proteasome inhibitor derived cell pools from mAb samples collected after 192 
hours of batch culture. The major N-glycan structures observed were G0F, G1Fa/b and G2F species, 
showing the presence of complex oligosaccharides with fucosylation, with minimal levels of G0 and 
Man5 observed (Figure 4C). In general the N-glycan profiles observed in the presence of the 
proteasome inhibitors were very similar to those in the control 37.5 M MSX and DMSO control. For 
the majority of the N-glycan species detected, the percentage of those present were within 2-3% of 
each other and all were within 10% of the controls (Figure 4C). Using this criteria, collectively the 
N-glycan data shows that cell pools generated in the presence of MSX and a proteasome inhibitor 
were not adversely impacted in terms of the ability of these cells to undertake the desired complex 
N-glycosylation of the model recombinant mAb molecule. 
3.4 Elevated mAb production from cell pools generated in the presence of proteasome 
inhibitors is maintained when these are later removed  
In order to determine if the improved productivity of cell pools generated in the presence of the 
proteasome inhibitors was maintained following further passaging of the pools, and if the continued 
presence of the proteasome inhibitors was required, cell pools generated from the cell pool 
constructions (Figure 3) were revived and sub-cultured without the inhibitors present. The higher 
productivity (compared to the controls) as a result of the presence of the inhibitors during cell pool 
development was maintained following routine subculture of the cells over a number of passages, 
although the exact magnitude of the increase between cultures did vary (Figure 5A). This suggests 
that the effects on titre are due to a higher producing population of cells being selected for during 
the cell line construction process and not due to a direct effect of the presence of the proteasome 
inhibitors on the cells influencing recombinant protein production. 
To demonstrate the reproducibility of the process, we undertook a further cell pool construction 
process using a wider range of proteasome inhibitor concentrations. Once again, this resulted in 
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increased productivity in those cell pools where the proteasome inhibitors epoxomicin and MG-132 
were present at various concentrations (Figure 5B-C). The increase in titre observed was similar 
when mAb yields were determined either immediately after culture with the inhibitors present or 
following subculture in the absence of the inhibitors. This provides further evidence that the presence 
of the proteasome inhibitors following transfection results in the emergence of a higher producing 
population of cells and that this population can then be maintained by subculture in the absence of 
the inhibitors.  
3.5 Culturing of host cells with proteasome inhibitors before recombinant cell pool 
construction does not result in the generation of cell pools with enhanced productivity  
We next investigated whether it was possible to evolve the host cell line in the presence of the 
proteasome inhibitors such that heritable properties that gave enhanced recombinant product yields 
were realized in the host cell as a result of pressure from the inhibitors. We hypothesized that 
populations within the host cell pool with a propensity to produce higher yields of recombinant protein 
may be evolved and selected for by culturing in the presence of the proteasome inhibitors prior to 
construction of recombinant mAb expressing cell pools. If this were realized, it would negate the 
need for addition of the inhibitors during the cell line construction process. The Lonza host cell line 
was therefore cultured in the same concentrations of the proteasome inhibitors (62.5 nM and 15.6 
nM MG-132 and 25 nM and 6.25 nM epoxomicin) for 5 to 7 passages. After this time, the resulting 
cell pools were then transfected with the cB72.3 construct either immediately after culture in the 
presence of the proteasome inhibitors, or following passage of the evolved host cell pools without 
the inhibitors present. The transient expression of cB72.3 from these cell pools was then evaluated 
and these did not show increased productivity over that shown when cells were evolved with DMSO 
alone (Figure 6). Although the impact of proteasome inhibitor evolution may give a different impact 
on transient expression of recombinant mAb compared to that of stable pools, the results suggest 
that the additional pressure of the recombinant protein production on the cells is likely to be required 
alongside the presence of the proteasome inhibitors to elicit the selective effects of the inhibitors. 
3.6 Application of proteasome selection pressure during cell pool construction of a difficult 
to express recombinant Fc-fusion protein results in the isolation of cell pools with enhanced 
productivity  
To determine if the beneficial effects on productivity of cell pool construction in the presence of 
proteasome inhibitors was product specific, a further cell pool construction was performed with a 
model Fc-fusion protein (FcFP) that was considered difficult to express (Budge et al., 2020). MG-
132 was added at 15.6, 31.25 and 62.5 nM concentrations and epoxomicin at 12.5 and 25 nM in 
addition to 37.5 M MSX. The transfections to which 25 nM epoxomicin was added did not result in 
the emergence of any colonies, however all other conditions resulted in pools emerging. These pools 
were expanded and batch culture assessment of growth and productivity undertaken with samples 
taken for assessment at 48, 96 and 168 hours for viable cell concentration, culture viability and FcFP 
titre (Figure 7). Lower viable cell concentrations were achieved with 31.25 and 62.5 nM MG-132 over 
96 hours of culture compared to the controls (in the absence of proteasome inhibitors), however 
these cultures did show an extended batch-culture lifetime. Viable cell concentration and culture 
viability for those cultures from 12.5 nM epoxomicin and 15.6 nM MG-132 were comparable to those 
treated with DMSO. FcFP titre and specific productivity were enhanced in those pools generated in 
the presence of 15.6 and 31.25 nM MG-132 in addition to the 37.5 M MSX. The magnitude of the 
increase in product concentration was approximately 50% for the best conditions.  
3.7 Those cell pools generated in the presence of proteasome inhibitors with enhanced mAb 
product yields show changes in gene expression that reflect decreased ERAD and UPR 
activity 
To investigate whether the impact of the presence of the proteasome inhibitors was related to 
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changes in the cellular folding capacity, ERAD or proteasome activity of the pools, commercially 
available RT2 profiler PCR arrays for the unfolded protein response were used to monitor the 
expression of key genes in these processes (Figure 8). The array allows the monitoring of a range 
of genes involved in pathways ranging from unfolded protein binding, ER protein folding and quality 
control, and translation to ERAD, ubiquitination and protein folding. Samples were taken from revived 
representative cell pools described in Figure 3 on days 3 and 6 of batch culture, the RNA extracted 
and then analyzed according to the manufacturer’s instructions using normalization with the Hprt1 
gene as this was determined to have the most stable expression levels. 
Comparison of day 3 samples between those treated with 25 nM epoxomicin and the control cell 
pool treated with DMSO only showed a decrease in the expression of genes involved in unfolded 
protein binding, ERAD and ubiquitination, as well as ER protein folding quality control and protein 
folding (Supplementary Table 1 and Supplementary Figures 2-7; (Kanehisa, 2000)). There were 
fewer differences between the cell pools treated with 62.5 nM MG-132 and DMSO treated pools at 
day 3, with only 2.74- and 2.19-fold decreases in Derlin-1 and Chac1 detected respectively, these 
genes being involved in ERAD and maintenance of protein folding (Kadowaki, 2015; Nomura, 2016; 
Ye, 2004) and demonstrating a similar trend to that observed with the epoxomicin treatment. Further, 
the beneficial impact of the MG-132 treatment was less marked than with epoxomicin in these 
cultures expressing the model antibody. Fewer differences were observed when comparing day 6 
DMSO treated control and epoxomicin treated pools. Approximate 2-fold increases were observed 
in Mapk9 and Ppil4 expression, these being involved in apoptosis and unfolded protein 
binding/protein folding respectively. Conversely, approximately 2-fold decreases were again 
observed in Derlin-1 and Edem1 expression, once again suggesting a decrease in the expression of 
genes involved in the ERAD process. No differences were observed when making a comparison of 
the 62.5 nM MG-132 treated pool with the DMSO treated cell pool for the Day 6 samples.  
Comparison within the treatment groups (e.g. within a culture with the same addition of inhibitor or 
control and how gene expression varied between day 3 and 6 of culture) revealed a greater change 
in the levels of gene expression. Comparison of the day 3 and 6 control DMSO treated samples 
showed an upregulation in genes involved in ERAD, ubiquitination, UPR protein folding and 
apoptosis (e.g. Derlin-1, Herpud1, Sel1l, Calr3, Chac1 and Ddit3) on day 6. Upregulation was also 
observed in samples taken from cultures treated with 25 nM epoxomicin on day 6 when compared 
to samples from the same cultures taken on day 3. This upregulation involved the same genes that 
were observed to be upregulate between day 3 and day 6 in the control cultures but the extent of 
upregulation was greater. Upregulation of genes between day 3 and day 6 in the 62.5 nM MG-132 
treated cell pool was to an intermediate extent when compared to the control and epoxomicin treated 
cell pools. 
 
4. Discussion  
We have investigated whether inhibition of proteasome activity during recombinant cell pool 
construction impacts on the subsequent product yields and quality from these cell pools compared 
to those generated in the absence of such inhibitors. There have been enormous advances in the 
ability of CHO cells to produce large amounts of high quality recombinant therapeutic proteins, 
particularly mAbs in recent years. However, some molecules remain DTE in CHO cells or any other 
system whilst many novel format molecules in development are expressed at lower yields than mAbs 
and are thus considered DTE (Budge, 2020; Mathias, 2020). Recent reports suggest that DTE 
antibodies can be incorrectly folded and degraded by the proteasome via ERAD (Mathias, 2020).  
Our initial proteasome inhibitor screening showed that the susceptibility of a panel of industrially 
relevant established recombinant CHO cells lines expressing a model monoclonal antibody to MG-
132 and epoxomicin differed. There was a positive correlation between culture viability or viable cell 
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concentration and mAb productivity when the cells were cultured in the presence of the proteasome 
inhibitors at the concentrations investigated. There are at least three possible explanations for this.  
First, that this is the result of the lower producing cell lines being less equipped in terms of the cellular 
machinery required to support high levels of recombinant protein synthesis and assembly, resulting 
in increased ERAD activity and an increased susceptibility to the presence of the inhibitors. Under 
this scenario, the inhibition of proteasome activity is more detrimental to these low producing cell 
lines. Second, that in high producing cell lines, the ERAD pathway may be less active or not be as 
over-loaded, due to enhanced folding and assembly capacity in these cell lines. Under this scenario, 
the negative impact of inhibiting the proteasome on cell fitness is reduced. This second hypothesis 
is in contradiction to the initial hypothesis that high levels of protein production in cells would be 
associated with high ER stress and conversely, high levels of ERAD activity (Travers, 2000).  Third, 
that higher producing cell lines have enhanced and ‘spare’ ERAD capacity and hence are less 
susceptible to ERAD inhibitors than low producing cell lines. 
From the data reported here, it is not possible to distinguish between these hypotheses. Previously 
a correlation between proteasome inhibition and productivity has been reported in myeloma cells, 
whereby those cells with relatively high IgG synthesis were more sensitive to proteasome inhibition 
than those with relatively low IgG synthesis, potentially due to accumulation of unfolded proteins 
(Meister, 2007). It is unclear why the results in this study show a different relationship between IgG 
expression and susceptibility to proteasome inhibitors. Our correlation analysis suggests that high 
producing recombinant CHO cell lines (higher cell specific productivity) are less sensitive to the 
presence of proteasome inhibition than low producer cell lines (as determine by correlation with the 
viable cell number maintained, Figure 2), suggesting that in high producing cell lines less protein 
degradation is required. This is likely a result of less misfolded protein being present in the ER and 
more protein being correctly processed in the ER leading to higher yields. High producing cell lines 
have previously been associated with elevated amounts of chaperones in recombinant protein 
expressing mammalian cell lines, and hence the fidelity of folding may be improved in these cells, 
allowing them to better facilitate high loads on the cellular machinery required to support enhanced 
recombinant protein production (Dinnis, 2006; Smales, 2004).  
We used this information to subsequently investigate if the presence of proteasome inhibitors during 
cell pool construction could be used as a selection pressure related to the amount of recombinant 
protein product. This novel selective pressure was applied in addition to a metabolic selection 
marker, in this case glutamine synthetase and its inhibitor MSX (Fan, 2012; Feary, 2017; Noh, 2018). 
The majority of combinations of MSX and either epoxomicin or MG-132 when applied to the selection 
process of cell pool construction post-transfection did not survive the selection process and 
subsequent culture. However, those populations that did emerge in the presence of either 62.5 nM 
MG-132 or 25 nM epoxomicin alongside 37.5 M MSX gave enhanced cB72.3 antibody titres after 
192 hours of batch culture when compared to those cultured with MSX alone. Importantly, the N-
glycosylation patterns were similar between mAb from the inhibitor and control pools suggesting 
there was no negative impact on glycosylation. Calculation of the specific cell productivity (Qp) of 
the cell pools confirmed that those pools generated in the presence of the proteasome inhibitors had 
an improved specific productivity compared to those cell populations generated with MSX selection 
alone. Again, these data suggest that the presence of proteasome inhibitors during cell pool 
construction selected for a higher producing population of cells. Importantly, we showed that after 
the initial cell selection process the continued presence of the inhibitors was not required to maintain 
the productivity of the pool and that the productivity traits were heritable. However, the emergence 
of improved productivity in the presence of the inhibitors did appear to require the recombinant 
product load to also be placed on the cell as directed evolution in the absence of the recombinant 
protein load with the inhibitors did not give enhanced transient expression. We suggest the increased 
pressure on the degradation and recycling system of the cell during recombinant protein production 
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allows the selection pressure of the proteasome inhibition to be successful. 
Finally, profiling of UPR and ERAD genes revealed that when samples from control cultures and 
those treated with proteasome inhibitors were compared on the same day of batch culture there was 
generally lower expression of UPR and ERAD genes in samples from cultures treated with 
proteasome inhibitors than in samples from the control cultures. When samples taken on two days 
of batch culture were compared (day 3 and 6) in control and proteasome inhibitor generated cell 
pools, there was an increased in the expression of the various genes regardless of treatment. This 
is likely a reflection of the difference in gene expression between different days of batch culture and 
increased recombinant protein production load on the cell and reduced growth, at the later culture 
day. The pool generated in the presence of 25 nm epoxomicin showed increased expression of the 
largest number of genes between day 3 and 6. Addition of proteasome inhibitors may therefore select 
for cells with an inherent folding capacity that matches recombinant protein demands, reducing the 
throughput into the ERAD pathway and material targeted for degradation.  
In conclusion, we have shown that the presence of proteasome inhibitors during the construction of 
cell pools expressing two different model molecules, including a difficult to express Fc-fusion protein, 
results in the generation of cell pools with enhanced productivity. The increased productivities 
generated, and the ability to select for higher producing cells, has the potential to improve the clonal 
selection during upstream processes in an industrial setting of difficult to express proteins in 
particular. Further elucidation of the mechanisms underpinning the increased productivity may also 
open up new cell engineering approaches to generate new host cells with an enhanced ability to 
produce such DTE proteins. 
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Figure 1. Assessment of proteasome inhibitor impact on model recombinant IgG producing 
CHO cell line growth parameters. 96 deep well plate experiments with a Lonza CHOK1SV® derived 
model IgG producing cell line were performed to monitor growth and culture viability in the presence 
of different concentrations of either epoxomicin (A,B) or MG-132 (C, D) proteasome inhibitors. Plates 
were left for 48 hours after seeding in an incubator under Lonza proprietary conditions before 
addition of the compounds at a range of concentrations. Samples were taken every 24 hours up to 
168 hours after addition of the drug and counted on a ViCell instrument to determine viable cell 
concentration (A, C) and culture viability (B, D). Note: the final DMSO concentration in epoxomicin 
and epoxomicin control experiments was 2.8% (v/v) whilst in MG-132 treated cells and controls it 
was 1.25% (v/v). 
Figure 2. Correlation analysis between susceptibility to proteasome and ERAD inhibitors, 
determined by viable cell concentration, and productivity data from fed-batch and bioreactor 
cultures for a panel of CHO cell lines producing a model monoclonal antibody. Analysis was 
performed in SigmaPlot 12.5 using linear regression analysis and Pearson Product Moment 
Correlation. Correlations found to be statistically significant (p<0.05) are shown. CHO mAb 
producing cell lines were cultured in the presence of the proteasome inhibitors in a 96DWP format 
and daily cell counts performed after addition of inhibitors (0.05 µM Epoxomicin and 0.5 µM MG-
132). Data from the 48 hour time point was used for the correlation analysis with historical 
productivity data (production concentration at harvest and specific productivity) generated at Lonza 
under fed batch and bioreactor culture conditions. A Correlation assessing cell concentration in the 
presence of 0.05 µM epoxomicin with cell specific production rates generated from fed batch culture. 
B Correlation assessing cell concentration in the presence of 0.05 µM epoxomicin with product 
concentration values generated from fed batch culture. C Correlation assessing cell concentration 
in the presence of 0.05 µM epoxomicin with cell specific production rate values generated from 
bioreactor culture. D Correlation assessing cell concentration in the presence of 0.05 µM epoxomicin 
versus product concentration values generated from bioreactor culture. E Correlation assessing cell 
concentration in the presence of 0.5 µM MG-132 with cell specific production rate values generated 
from fed batch culture. F Correlation assessing culture viability in the presence of 0.5 µM MG-132 
with specific production rate values generated from fed batch culture.  
Figure 3. A-B Growth characteristics of cell populations generated using a cell pool 
construction process with MSX and varying proteasome inhibitors and concentrations. The 
Lonza CHOK1SV GS-KO® cell pools expressing the model cB72.3 monoclonal antibody were 
cultured in duplicate at 37oC with 5% CO2 and shaking at 140 rpm and cell counts were performed 
every 48-72 hours following cell pool construction with proteasome inhibitors in addition to MSX. C: 
Antibody concentrations from cell populations generated using a cell pool construction 
process with MSX and varying proteasome inhibitors and concentrations. Lonza CHOK1SV 
GS-KO® cell pools expressing cB72.3 were cultured and a Protein A HPLC analysis performed with 
supernatant collected after 192 hours of culture following cell pool construction with proteasome 
inhibitors in addition to MSX selection pressure. ** denotes a statistical significance (p<0.01) 
determined by one way ANOVA analysis with Tukey grouping using Minitab 17 software. 
Figure 4. N-Glycan analysis to assess product characteristics of cell populations generated 
using a cell pool construction process with MSX and varying proteasome inhibitors and 
concentrations. Lonza CHOK1SV GS-KO® cell pools expressing cB72.3 were cultured and glycan 
analysis performed accordingly to Lonza internal protocols with supernatant collected after 192 hours 
of culture. Results from analysis of mAb material from duplicate cultures are shown.  
Figure 5. (A) Estimated Qmab values for cell populations generated using a cell pool 
construction process with MSX and varying proteasome inhibitors and concentrations during 
routine subculture. Lonza CHOK1SV GS-KO® cell pools expressing cB72.3 were cultured and 
Protein A Octet analysis performed on supernatant collected during routine subculture following cell 
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pool construction with proteasome inhibitors in addition to MSX selection pressure. Estimated Qmab 
values were determined by dividing the titre (µg/ml) by the cell count (x106 cells/ml). Specific 
productivities for the cell populations generated using MSX and varying proteasome inhibitor 
concentrations immediately after presence of the inhibitor (B) and following routine 
subculture (C). Protein A Octet analysis was performed on supernatant collected at 48, 96 and 168 
hours of batch culture of Lonza CHOK1SV GS-KO® cell pools grown in triplicate and expressing 
cB72.3 following cell pool construction with proteasome inhibitors in addition to MSX selection 
pressure. Specific productivity values were calculated for each cell pool both immediately after 
culture in the presence of the inhibitors and following subculture where the inhibitors had been 
removed.  
Figure 6. Specific productivities from transient transfection with cB72.3 of Lonza CHOK1SV 
GS-KO® host cells after directed evolution by culturing in the presence of proteasome 
inhibitors. Lonza CHOK1SV GS-KO® host cells were cultured in the presence of proteasome 
inhibitors for 5-7 passages and then transiently transfected with cB72.3. Samples were taken at 48, 
96 and 168 hours post transfection. Inhibitors were also removed from the GSKO® host cultures 
(previously cultured in the presence of the inhibitors) for three routine subcultures before the 
transient transfection was repeated and samples collected at 48, 96 and 168 hours post transfection, 
to determine if the continued presence of the inhibitor was required. Protein A Octet analysis was 
performed with supernatant collected and specific productivities calculated. 
Figure 7. (A & B) Growth characteristics of cell populations expressing a model Fc-fusion 
protein generated using a cell pool construction process with MSX and varying proteasome 
inhibitors and concentrations. Lonza CHOK1SV GS-KO® cell pools expressing a model Fc-fusion 
protein were cultured in duplicate at 37oC with 5% CO2 and shaking at 140 rpm and cell counts 
performed every 48-72 hours following cell pool construction with proteasome inhibitors in addition 
to MSX. (C) Product concentrations achieved from cell populations generated using a cell 
pool construction process with MSX and varying proteasome inhibitors and concentrations. 
Lonza CHOK1SV GS-KO® cell pools expressing a model Fc-fusion protein were cultured and Octet 
Protein A assay performed on supernatant collected after 48, 96 and 168 hours of culture following 
cell pool construction with proteasome inhibitors in addition to MSX selection pressure. Averages 
were derived from duplicate cultures under each condition. (D) Calculated specific productivities 
achieved from cell populations generated using a cell pool construction process with MSX 
and varying proteasome inhibitors and concentrations. Specific productivities were derived from 
the acquired growth and titre data for the above time-course.  Averages were derived from individual 
specific productivities from duplicate cultures under each condition. 
Figure 8: Scatterplots comparing the normalised expression of each gene on the array 
between two conditions. Qiagen Unfolded Protein Response RT2 Profiler PCR Array was 
performed on total RNA extracted for cell pools generated using proteasome selection during cell 
pool construction. Cells were cultured at 37oC with 5% CO2 and shaking at 140 rpm. A shows 
represents duplicate samples of day 3 culture with 25 nM Epoxomicin and 37.5 µM MSX treatment 
versus duplicate samples of day 3 culture with DMSO and 37.5 µM MSX treatment; B shows 
duplicate samples of day 3 culture with 62.5 nM MG-132 and 37.5 µM MSX treatment versus 
duplicate samples of day 3 culture with DMSO and 37.5 µM MSX treatment; C shows duplicate 
samples of day 6 culture with 25 nM Epoxomicin and 37.5 µM MSX treatment versus duplicate 
samples of day 6 culture with DMSO and 37.5 µM MSX treatment; D shows duplicate samples of 
day 6 culture with 62.5 nM MG-132 and 37.5 µM MSX treatment versus duplicate samples of day 6 
culture with DMSO and 37.5 µM MSX treatment; E shows duplicate samples of day 6 cultures with 
DMSO and 37.5 µM MSX versus duplicate samples of day 3 culture with DMSO and 37.5 µM MSX 
treatment; F shows duplicate samples of day 6 culture with 25 nM Epoxomicin and 37.5 µM MSX 
treatment versus represents duplicate samples of day 3 culture with 25 nM Epoxomicin and 37.5 µM 
MSX treatment; and G shows duplicate samples of day 6 culture with 62.5 nM MG-132 and 37.5 µM 
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MSX treatment versus duplicate samples of day 3 culture with 62.5 nM MG-132 and 37.5 µM MSX 
treatment, all using auto HKG normalisation in the analysis software. Spots outside the dotted 95% 
confidence interval lines highlight genes whose expression was significantly different between 
sample sets (upregulated shown by yellow spots above upper line, downregulation shown by blue 
spots below lower line). 
 
